PHOX2B promoter methylation was also detected in 2/18 tumuors analysed. Treatment with the demethyling agent 5-Aza-20-deoxycytidine (5-Aza-dC) restored PHOX2B transcription in PHOX2Bnegative cell lines, showing that gene silencing was due to aberrant hypermethylation. We conclude that aberrant CpG dinucleotide methylation of PHOX2B is an alternative mechanism at least as frequent as coding sequence mutations for inactivation of PHOX2B in sporadic NB. IVS. Constitutional and tumour DNA were extracted using standard protocols. We included a patient from a two generation family with predisposition to NB due to a germline PHOX2B gene mutation (NBAF5, ). Table 1 2
Materials and methods

Patients
Sequence analysis
We screened the coding sequence of the PHOX2B gene by direct DNA sequencing, as described elsewhere. We studied a 533 bp 1 sequence of the promotor region that is extremely conserved among species (97 between human and chicken at nucleotide level). The [ ]
LOH analysis
Matched constitutional and tumour DNA samples were PCR amplified using microsatellitte markers of the G n thon database é é D4S2974 and D4S1536 flanking the PHOX2B locus. D4S1536 is 4.1Mb centromeric to PHOX2B and D4S2974 is 95 Kb telomeric to PHOX2B. Fluorescent PCR products were electrophoresed and analysed on an automatic sequencer (ABI377, Applied Biosystems, Foster City, USA).
Cell culture
Cell lines were cultured at 37 C, 5 CO2, in Dulbecco s modified essential medium (DMEM; Invitrogen/Gibco, NY) containing 10°%
' % foetal calf serum, 292 g/ml L-glutamine, 1 100X MEM (non-essential amino acids medium, Invitrogen/Gibco), and 0.5 penicillin μ % % solution. Primary human neural crest cells were cultured for 3 weeks in FGF2-and EGF-containing embryonic stem cell medium with modifications available upon request.
PHOX2B expression in NB cell lines and tumours
Total RNA was isolated from cell lines and tumours by use of RNAzolB (Invitrogen). PHOX2B expression was first obtained from microarray on Affymetrix HG-U133 Plus 2.0 arrays. Data from 55 neuroblastic tumours were normalised using the GCRMA method. Detailed methods will be detailed elsewhere (I. Janoueix-Lerosey and O. Delattre, manuscript in preparation). In addition, RT-PCR detection of PHOX2B mRNA was performed in order to validate these data in 13 NB cell lines and eight tumours ( ). First strand Fig. 1a cDNA synthesis was performed on 2 g of total RNA in a volume of 20 l by use of RNA kit, Applied Biosystems and oligo(dT) primers.
The specific primers used for mRNA amplification were designed within exons 2 and 3, as follows: 5 -GAGGCGCGAGTCCA -CACACTACTTAAAAATAATAA AAATTAAAT-3 (reverse). PCR conditions were standard with an annealing temperature of 58 _C.
′ PCR products were loaded on a 2 agarose gel and directly visualised under UV illumination. PCR products were cloned in a TA cloning % vector (Promega, Madison, WI) and ten individual clones were sequenced for each sample.
Treatment of NB cells with 5-Aza-dC
Cells were seeded, allowed to attach over a 24 h period, and treated for 72 h with the demethyling reagent 5-Aza-dC (Sigma) at a final concentration of 1 lM. After the treatment period the medium was removed and RNAs were extracted.
inserm-00323027, version 1 -19 Sep 2008
Results
Mutation and LOH at the PHOX2B locus in neuroblastoma
As previously reported, a heterozygous frameshift mutation was identified in the SK-N-SH cell line (721 740del20nt,3). No mutation, -either somatic or germinal, of the PHOX2B coding sequence and promoter conserved region were identified in the other 12 NB cell lines and the 45 individuals with sporadic NB. A heterozygous missense mutation (R100L) was identified in patient NBAF5 originating from a family predisposed to NB over three generations. No second molecular event could be identified in tumoural DNA ( ). We detected Table 1 three known synonymous base substitutions, 552C > T(S184S), 750G > A (A250A) and 870C > A (P290P). In one patient, the P290P variant was heterozygous in constitutional DNA and homozygous in tumoural DNA. LOH was confirmed in this patient and identified in four other tumours (5/46 tumours, 10.8 ) with fluorescent microsatellite markers. % PHOX2B expression in NB cell lines and tumours PHOX2B expression levels were obtained from Affymetrix HG U133 Plus 2.0 arrays. High level of PHOX2B expression was found in 10/13 cell lines and 15/17 tumours whereas no expresion could be detected in three cell lines and two tumours ( ). PHOX2B Table 1 expression was examined by RT-PCR in 13 NB cell lines and eight tumours and two neural crest-derived tissues: adrenal gland medulla (MSR) and human trunk-level neural crest cells. These primary, non-transformed cells were derived from a human embryo at 28 days of development with a normal karyotype. Loss of expression was confirmed by the absence of PHOX2B mRNA transcripts in 3/13 cell lines (SK-N-SH, SK-N-BE and GIMEN) whereas PHOX2B cDNAs were visualised in all other cell lines and non-cancerous adrenal (MSR) and neural crest cells (NC) (
). PHOX2B was silenced in three tumours: one ganglioneuroma (NBAF21), one ganglioneuroblastoma Fig. 1a (NBAF38) and one NB (NB10) ( ). 
Restoration of PHOX2B expression in negative cell lines by 5-Aza-dC
5-Aza-dC, a methyltransferase inhibitor, was used to investigate whether PHOX2B expression could be restored cell lines for which PHOX2B was not expressed. PHOX2B mRNA expression levels, analysed by RT-PCR, were restored in SK-N-BE and GIMEN cell lines, while no re-expression was observed for SKN-SH.
Discussion
This study of a series of 13 cell lines and 46 neuroblastic tumours aimed to determine the role of PHOX2B in sporadic NB. PHOX2B, not known so far for being either a tumour-suppressor gene or a proto-oncogene, is the first predisposing gene identified in NB. Most mutations occur in familial and syndromic NB cases. A heterozygous germline mutation was found in about 20 of published pedigrees % and reached 50 when HSCR is associated with NB either in the index case or relatives. , , , However, germline PHOX2B mutations Somatic PHOX2B mutations have also been described in NB.3 In the series of 45 sporadic NB cases we report, no PHOX2B gene mutations were identified either in the coding sequence or the promoter region. LOH at the PHOX2B locus could be detected in 5/46
cases.
This ratio of about 10 has to be balanced with the known high rate of chromosomal rearrangement in NB. It is worth noting that % LOH of the short arm of chromosome 4 is found in roughly 20 of NB, but PHOX2B is centromeric to the smallest region of overlap % (SRO). , 15 16 We subsequently asked the question of epigenetic events at the PHOX2B locus and identified clonal aberrant CpG island methylation of the promoter in 2/13 NB cell lines and 2/18 tumours (ganglioneuroma in one case and NB stage II in one case). The demethylating drug 5-Aza-dC reinduced PHOX2B expression in NB cell lines, suggesting that PHOX2B methylation correlates with gene silencing.
Moreover, it is well established that DNA demethylating agents as 5-Aza-dC induce adrenergic differentiation in NB cell lines17 and have an antiproliferative effect in mouse NB models. Hypermethylation and downregulation of potential tumour-suppressor genes such as 18 genes involved in cell-cycle control or apoptosis is often associated with a poor outcome in NB. , , 9
We first considered PHOX2B as a potential tumour-suppressor gene since, i) at least some mutations identified in syndromic or familial NB cases (i.e. missense mutations of the homeodomain) are likely loss-of-function mutations, ii) a second hit model has been ' '
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proposed in NB21 and, iii) some constitutional LOH at chromosome 4p encompass the PHOX2B locus. However, in patients with 4
germinal PHOX2B mutation, neither a secondmutation nor LOH or aberrant promoter hypermethylation in the tumours have been identified as reported earlier.2 PHOX2B has been shown to promote differentiation by controlling G1-S transition during cell cycle of sympathetic neuroblast precursors and is an essential regulator of normal autonomic nervous system development. Mice with a homozygous inactivation of 22 23 Phox2b fail in proper differentiation of the sympathetic nervous system. A gain-of-function or a dominant negative effect of PHOX2B frameshift mutations is not, however, ruled out. When tested, mutant transcripts were present and stable. While mutant proteins localised 2 to the nucleus, we observed some ability to bind DNA for two of the three PHOX2B frameshift mutations tested in vitro, although transactivation of the dopamine betahydroxylase promoter was always severely impaired. Moreover, Bachetti and coworkers reported an 24 increased transactivation of the PHOX2A promoter for proteins resulting from frameshift mutations when compared to the wild type protein.
PHOX2B is expressed not only in neural crest cells but also in mature sympathetic tissue of adrenal gland ( ). 25 Fig. 1a and1 Methylation-associated repression of PHOX2B could result in a differentiation block of sympathetic neuroblasts.
Interestingly, NB10 patient had HSCR. We found aberrant homozygous PHOX2B promoter methylation on the tumour sample DNA while neither a mutation nor a deletion could be identified on either germinal or tumour DNA. Interestingly, PHOX2B was not methylated on lymphocyte DNA. We could speculate that PHOX2B methylation occurred during embryonic development and is responsible for both HSCR and NB development. As malignant transformation of cells could happen at different stages of tissue maturation, aberrant methylation may contribute to the diversity that characterises NB and other genes of the RET-PHOX2B pathway could be implicated.
Interestingly, aberrations in the p53/MDM2/p14 (ARF) pathway have recently been described in the two NB cell lines where PHOX2B
was found methylated ; a p53 mutation in SKNBE (2) However, down-regulation of PHOX2B was not always associated with hypermethylation. In SK-N-SH, the mutation is heterozygous and no PHOX2B expression could be detected. This result is discordant with the one reported by van Limpt and coworkers who observed the expression of both wild-type and mutant cDNAs in this cell line. However, they observed a PHOX2B gene silencing in the SHEP cell line, a stable subclone of SK-N-SH and also carrying the frameshift mutation. One could speculate on aberrant hypermethylation outside of the promoter region studied. However, it is worth noting that no expression of H-ASH1 could be detected either in the SK-N-SH cell line or in NBAF38 tumour (data not shown). This could also contribute to PHOX2B down-regulation. Finally, one can speculate on the effects of other mechanisms such as micro RNAs . Fig. 2 Genetic heterogeneity in predisposition to neuroblastic tumours is likely. The high reocurence of loss of heterozygosity for chromosomes 1p36 and 11q23 supported the existence of putative tumour-suppressor genes within these regions. However, these loci do Fig. 1  (a) mRNA in NB cell lines. mRNA is detected in 10/13 cell lines as in human adrenal gland medulla (MSR) and PHOX2B PHOX2B
non-transformed human neural crest cells (NC). No expression could be observed in three NB cell lines; SKNSH, SKNBE and GIMEN. (b) Bisulfite sequencing analysis of the methylation status of the 12 CpG from the start site. One microgram of tumour DNA was denatured by sodium hydroxide and modified by sodium bisulfite treatment, which converts unmethylated cytosines to uracil. Bisulfite treated DNA was amplified using specific primers (added in methods). promotor is 100 methylated in SKNBE and GIMEN but not in other cell PHOX2B % lines. All the 12 CpG dinucleotide are methylated in two primary tumours NBAF21 and NB10. All ten clones showed identical methylation in each sample. methylated cytosine non-methylated cytosine.
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